Metastatic disease: a drug discovery perspective

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Disseminated tumor cells are common at diagnosis, often after prior therapy.
• Metastases genetically evolve and interact with the tumor microenvironment.
• Current anti-cancer drug profiling inadequately considers these metastatic features.

Purpose of the Study:

• To discuss the unique characteristics of metastatic disease.
• To review existing preclinical model systems for drug profiling.
• To recommend improvements for validating drugs targeting overt metastatic disease.

Main Methods:

• Review of current preclinical drug profiling methodologies for metastatic disease.
• Analysis of existing model systems for their suitability in metastatic research.
• Discussion of current know-how and future possibilities in drug validation.

Main Results:

• Existing drug profiling methods do not fully account for metastatic evolution and microenvironment interactions.
• A gap exists between current preclinical models and the complexity of overt metastatic disease.
• There is a need for refined drug validation processes.

Conclusions:

• Current drug profiling for metastatic disease requires enhancement.
• Improved preclinical models and profiling strategies are crucial for developing effective anti-cancer therapies.
• A refined profiling process can better validate drugs for patients with overt metastatic disease.